Stiefel Usha, Nerandzic Michelle M, Pultz Michael J, Donskey Curtis J
Research Service, Louis Stokes Cleveland Veterans Affairs Medical Center, Cleveland, Ohio, USA Division of Infectious Diseases, Department of Medicine, Case Western Reserve University, Cleveland, Ohio, USA
Research Service, Louis Stokes Cleveland Veterans Affairs Medical Center, Cleveland, Ohio, USA.
Antimicrob Agents Chemother. 2014 Aug;58(8):4535-42. doi: 10.1128/AAC.02782-14. Epub 2014 May 27.
Antibiotics that are excreted into the intestinal tract may disrupt the indigenous intestinal microbiota and promote colonization by health care-associated pathogens. β-Lactam, or penicillin-type, antibiotics are among the most widely utilized antibiotics worldwide and may also adversely affect the microbiota. Many bacteria are capable, however, of producing β-lactamase enzymes that inactivate β-lactam antibiotics. We hypothesized that prior establishment of intestinal colonization with a β-lactamase-producing anaerobe might prevent these adverse effects of β-lactam antibiotics, by inactivating the portion of antibiotic that is excreted into the intestinal tract. Here, mice with a previously abolished microbiota received either oral normal saline or an oral cephalosporinase-producing strain of Bacteroides thetaiotaomicron for 3 days. Mice then received 3 days of subcutaneous ceftriaxone, followed by either oral administration of vancomycin-resistant Enterococcus (VRE) or sacrifice and assessment of in vitro growth of epidemic and nonepidemic strains of Clostridium difficile in murine cecal contents. Stool concentrations of VRE and ceftriaxone were measured, cecal levels of C. difficile 24 h after incubation were quantified, and denaturing gradient gel electrophoresis (DGGE) of microbial 16S rRNA genes was performed to evaluate the antibiotic effect on the microbiota. The results demonstrated that establishment of prior colonization with a β-lactamase-producing intestinal anaerobe inactivated intraintestinal ceftriaxone during treatment with this antibiotic, allowed recovery of the normal microbiota despite systemic ceftriaxone, and prevented overgrowth with VRE and epidemic and nonepidemic strains of C. difficile in mice. These findings describe a novel probiotic strategy to potentially prevent pathogen colonization in hospitalized patients.
排泄到肠道中的抗生素可能会破坏肠道内的原生微生物群,并促进医疗保健相关病原体的定植。β-内酰胺类抗生素,即青霉素类抗生素,是全球使用最广泛的抗生素之一,也可能对微生物群产生不利影响。然而,许多细菌能够产生使β-内酰胺类抗生素失活的β-内酰胺酶。我们推测,预先用产β-内酰胺酶的厌氧菌在肠道定植,可能会通过使排泄到肠道中的那部分抗生素失活,来预防β-内酰胺类抗生素的这些不良反应。在此,先前微生物群已被消除的小鼠,连续3天口服生理盐水或口服产头孢菌素酶的嗜热栖粪杆菌菌株。然后,小鼠接受3天的皮下头孢曲松治疗,随后口服耐万古霉素肠球菌(VRE),或处死小鼠并评估鼠盲肠内容物中艰难梭菌流行株和非流行株的体外生长情况。测量VRE和头孢曲松的粪便浓度,对孵育24小时后的盲肠中艰难梭菌水平进行定量,并对微生物16S rRNA基因进行变性梯度凝胶电泳(DGGE),以评估抗生素对微生物群的影响。结果表明,预先用产β-内酰胺酶的肠道厌氧菌定植,在使用这种抗生素治疗期间使肠道内的头孢曲松失活,尽管全身性使用头孢曲松,但仍能使正常微生物群恢复,并防止小鼠中VRE以及艰难梭菌流行株和非流行株过度生长。这些发现描述了一种潜在预防住院患者病原体定植的新型益生菌策略。